Enbrel (Etanercept) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Enbrel (Etanercept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Enbrel (Etanercept) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Enbrel (etanercept) is a biologic medication that treats various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein involved in inflammation. It is a synthetic version of a naturally occurring protein in the body, designed to bind to TNF and block its interaction with its receptors, reducing inflammation. Enbrel is usually administered through subcutaneous injection, either by a healthcare professional or by patients themselves at home.
Major players operating in the enbrel (etanercept) market are Amgen Inc; Pfizer Inc. North America was the largest region in the enbrel (etanercept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel (etanercept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enbrel (etanercept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.The primary types of enbrel (etanercept) include brand drugs and biosimilars. It is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis by blocking TNF. Enbrel is available in both liquid solution and powder for injection forms.The growth observed during the historic period can be attributed to the approval of multiple indications, strong adoption by physicians, the introduction of patient-friendly injection devices, a growing healthcare focus on cost-effective treatments for chronic diseases, extensive clinical trials, and positive outcomes.Market growth during the forecast period can be driven by the aging global population, the increasing prevalence of autoimmune diseases, rising preference for biologics, the introduction of biosimilars, and increased government funding and insurance coverage. Key trends during this period include its use in pediatric populations, a rise in home-based treatments, integration of digital health, combination therapy approaches, and advancements in genomics and biomarker research.The surging prevalence of autoimmune conditions is expected to significantly propel the growth of the enbrel (etanercept) market. Autoimmune conditions, where the immune system mistakenly attacks the body's healthy tissues, are increasing due to factors such as genetic susceptibility, environmental triggers, and improved diagnosis and awareness. Enbrel, which inhibits tumor necrosis factor-alpha (TNF-a), is highly effective in treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, Enbrel helps reduce inflammation, alleviate symptoms, and slow disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 Australians were living with rheumatoid arthritis in 2022. The increasing prevalence of such conditions will continue to drive demand for enbrel.A key trend in the enbrel (etanercept) market is the development of innovative TNF inhibitors to manage autoimmune diseases. TNF inhibitors block the TNF protein, which is responsible for inflammation and immune responses, thereby helping to reduce symptoms like joint swelling and pain. In October 2023, Amgen Inc. received U.S. Food and Drug Administration (FDA) approval for Enbrel to manage juvenile psoriatic arthritis (JPsA) in children aged two and older. This approval marks a significant advancement in the use of Enbrel for younger patients.Key Topics Covered: 1. Executive Summary2. Enbrel (Etanercept) Market Characteristics3. Enbrel (Etanercept) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Enbrel (Etanercept) Market Trends and Strategies5. Enbrel (Etanercept) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Enbrel (Etanercept) Growth Analysis and Strategic Analysis Framework6.1. Global Enbrel (Etanercept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Enbrel (Etanercept) Market Growth Rate Analysis6.4. Global Enbrel (Etanercept) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Enbrel (Etanercept) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Enbrel (Etanercept) Total Addressable Market (TAM)7. Global Enbrel (Etanercept) Market Pricing Analysis & Forecasts8. Enbrel (Etanercept) Market Segmentation8.1. Global Enbrel (Etanercept) Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Brands Drugs
Biosimilar Drugs
8.2. Global Enbrel (Etanercept) Market, Segmentation by Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Liquid Solution
Powder For Injections
8.3. Global Enbrel (Etanercept) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
9. Global Enbrel (Etanercept) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Enbrel (Etanercept) Market Regional and Country Analysis10.1. Global Enbrel (Etanercept) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Enbrel (Etanercept) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/whnv8t
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
LuluTox Detox Tea Announces Official Website Update Featuring Natural Daily Supplement for Full-Body Detox and Digestive Support
Caffeine-Free Herbal Tea Supplement Supports Gentle Full-Body Detox, Bloating Relief, and Digestive Wellness HYDE PARK, June 09, 2025 (GLOBE NEWSWIRE) -- LuluTox Detox Tea, a U.S.-based wellness brand dedicated to natural detox solutions, has launched an updated version of its official website to better inform customers about its herbal daily-use tea supplement. Designed to support full-body detox and digestive balance, the caffeine-free tea formula is now available to consumers across the country through its verified online storefront. According to the official website ( LuluTox Detox Tea works with the body's natural systems to help promote internal cleansing, reduce occasional bloating, and support regular digestion. Created for individuals seeking a simple addition to their daily health routine, the supplement is delivered in the form of herbal tea bags for convenient, hot or cold preparation. 'We believe wellness should be as natural and uncomplicated as possible,' said a LuluTox representative. 'Our detox tea reflects that philosophy—providing support for gut health, gentle detoxification, and daily energy without the need for harsh cleanses or extreme dietary changes.' The product is manufactured in facilities that follow strict quality and safety protocols. Its herbal formulation is crafted from natural plant-based ingredients traditionally used to assist the body's detox pathways and digestive functions. As noted on the product site, LuluTox Detox Tea includes a satisfaction guarantee for new customers. Visitors can access comprehensive product information, usage guidance, and secure purchasing options by visiting the official LuluTox website. About LuluTox Detox Tea LuluTox Detox Tea is a New York-based wellness company focused on delivering simple, effective detox support through nature-inspired formulations. The brand offers herbal-based supplements designed for daily use, blending transparency, convenience, and wellness support into every product. Product and Contact Information Brand: LuluTox Detox TeaWebsite: support@ +1 (888) 828-8952Mailing Address: 3979 Albany Post Road, Ste 2, Unit #2277, Hyde Park, NY 12538 CONTACT: Email: support@ Phone: +1 (888) 828-8952Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
MochaLean Announces Official Website Update Featuring Natural Daily Supplement for Weight Management Support
New U.S.-Available Metabolism Support Supplement Designed to Promote Appetite Control and Daily Energy Balance Naturally TALLMADGE, June 09, 2025 (GLOBE NEWSWIRE) -- MochaLean™, a U.S.-based wellness brand, has updated its official website to share new information about its daily supplement developed to support healthy weight management in adults. Now available in the U.S., the plant-based formula is designed for individuals seeking a natural, routine-friendly wellness solution. According to the official product website ( MochaLean™ is intended to work in harmony with the body's internal systems to support metabolism, appetite regulation, and energy levels. The company positions the supplement as a convenient, daily-use formula that integrates into everyday life without requiring restrictive diets or complicated routines. 'We believe health support should be simple and natural,' said a company spokesperson. 'This product reflects our commitment to natural wellness and quality-driven formulation.' The company states that MochaLean™ is manufactured in facilities that follow strict safety and quality control protocols. The formulation is composed of ingredients selected to align with common adult wellness goals, such as metabolic support, healthy energy maintenance, and appetite balance. As noted on the product website, MochaLean™ includes a satisfaction guarantee for new customers. Those interested in exploring the formula's intended uses or ordering directly can find full details, FAQs, and purchasing options at the official site. About MochaLean™ MochaLean™ is a U.S.-based wellness brand focused on delivering natural, easy-to-use supplements that support daily health routines. Committed to transparency and simplicity, the company aims to provide effective solutions that help adults feel their best. Product and Contact Information Brand: MochaLean™Website: support@ 1-800-390-6035Return Address: Fulfillment House, 285 Northeast Ave, Tallmadge, OH 44278, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: support@ Phone: 1-800-390-6035 Return Address: Fulfillment House, 285 Northeast Ave, Tallmadge, OH 44278, USA
Yahoo
44 minutes ago
- Yahoo
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video conference, please register online using this registration link. The presentation and conference details will also be available under 'Events & Presentations' in the Investors section of the Roivant website at The archived webcast will be available on Roivant's website after the conference call. About Priovant Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted therapy. Brepocitinib is administered as a once-daily oral therapy. It has been dosed in over 1,400 subjects and has generated positive data in seven Phase 2 studies. Brepocitinib is currently being evaluated in dermatomyositis (Phase 3), non-infectious uveitis (Phase 3), and cutaneous sarcoidosis (Phase 2). About Roivant Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit Roivant Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts:InvestorsKeyur MediaStephanie ResearchDaniel Herz-Roiphe
